Vitamin D may not help your heart

While previous research has suggested a link between low levels of vitamin D in the blood and an increased risk of cardiovascular disease, a new Michigan State University study has found that taking vitamin D supplements did not reduce that risk. The large-scale study, published in the Journal of the American Medical Association Cardiology, found that vitamin D supplements did not decrease the incidence of heart attacks, strokes or other major adverse cardiovascular events.

"We thought it would show some benefit," said Mahmoud Barbarawi, a clinical instructor in the MSU College of Human Medicine and chief resident physician at Hurley Medical Center in Flint, Michigan. "It didn't show even a small benefit. This was surprising."

His finding was consistent for both men and women and for patients of different ages.

Many earlier studies have found an association of low levels of vitamin D in the blood and an increased risk of cardiovascular disease, suggesting that vitamin D supplements might reduce that risk.

Barbarawi led a team of researchers and reviewed data from 21 clinical trials, including more than 83,000 patients. Half the patients were administered vitamin D supplements, and half were given placebos. The meta-analysis of data showed no difference in the incidences of cardiovascular events or all causes of death between the two groups.

Vitamin D sometimes is known as the sunshine vitamin, because human skin makes vitamin D when exposed to the sun. Thus, those living farthest from the equator tend to have lower levels of vitamin D in their blood.

While some studies have found a link between low levels of the vitamin and an increased risk of adverse cardiovascular events, Barbarawi's study suggests that other factors, such as outdoor physical activity and nutritional status, might explain the association.

Barbarawi also noted that even though his findings showed no effect on heart health, some patients, such as those being treated for osteoporosis, still might benefit from the supplements.

As a result, he suggests that doctors and patients think twice about taking the vitamin to minimize the chances of a heart attack or other cardiovascular issues.

"We don't recommend taking vitamin D to reduce this risk," Barbarawi said.

Mahmoud Barbarawi, Babikir Kheiri, Yazan Zayed, Owais Barbarawi, Harsukh Dhillon, Bakr Swaid, Anitha Yelangi, Saira Sundus, Ghassan Bachuwa, Mohammad Luay Alkotob, JoAnn E Manson.
Vitamin D Supplementation and Cardiovascular Disease Risks in More Than 83 000 Individuals in 21 Randomized Clinical Trials: A Meta-analysis.
JAMA Cardiol. Published online June 19, 2019. doi: 10.1001/jamacardio.2019.1870.

Most Popular Now

Preventing tumor metastasis

Researchers at the Paul Scherrer Institute, together with colleagues from the pharmaceutical company F. Hoffmann-La Roche AG, have taken an important step towards the dev...

A new drug could revolutionize the treatment of ne…

The international team of scientists from Gero Discovery LLC, the Institute of Biomedical Research of Salamanca, and Nanosyn, Inc. has found a potential drug that may pre...

Interactions discovered in cells insulating nerve …

Schwann cells form a protective sheath around nerve fibres and ensure that nerve impulses are transmitted rapidly. If these cells are missing or damaged, severe neurologi...

Breast cancer can form 'sleeper cells' after drug …

Breast cancer medicines may force some cancer cells into 'sleeper mode', allowing them to potentially come back to life years after initial treatment. These are the early...

Anniversary of the pivotal RE-LY® trial marks a de…

Boehringer Ingelheim today announces the ten-year anniversary of the RE-LY® trial publication(1-3) recognising the contribution made in the decade since by patients, heal...

Experimental validation confirms the ability of ar…

Insilico Medicine, a global leader in artificial intelligence for drug discovery, announced the publication of a paper titled, "Deep learning enables rapid identification...

AstraZeneca agrees to buy US FDA Priority Review V…

AstraZeneca announced that it has agreed to buy a US Food and Drug Administration (FDA) Priority Review Voucher (PRV) for a total cash consideration of $95m from a subsid...

Boehringer Ingelheim eExpands KRAS cancer program …

Boehringer Ingelheim and Lupin Limited (Lupin) announced a licensing, development and commercialization agreement for Lupin's MEK inhibitor compound (LNP3794) as a potent...

Pfizer invests half billion dollars to advance sta…

Pfizer announced an additional half billion dollar investment for the construction of its state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina...

FDA grants Fast Track designation for Farxiga in c…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of Farxiga (dapagliflozin) to delay the ...

The Pfizer Foundation invests in 20 organizations …

The Pfizer Foundation announced 20 grants* to help non-governmental organizations (NGOs), non-profits and social enterprises address critical health challenges related to...

Tagrisso approved in China as a 1st-line treatment…

AstraZeneca today announced that it has received marketing authorisation from China's National Medical Products Administration (NMPA) for Tagrisso (osimertinib) as a 1st-...